FFR vs. icecg in Coronary Bifurcations (FIESTA) - preliminary results. Dobrin Vassilev MD, PhD National Heart Hospital Sofia, Bulgaria

Similar documents
FFR vs icecg in Coronary Bifurcations FIESTA ClinicalTrials.gov Identifier: NCT

FFR-guided Jailed Side Branch Intervention

Side Branch Occlusion

POLish Bifurcation Optimal treatment Strategy randomized Study (POLBOSS) - Interim analysis

LM stenting - Cypher

Why I try to avoid side branch dilatation

Are Asian Patients Different? - Updates Of Biomatrix Experience In Regional Settings: BEACON II (3 Yr F up) &

Lessons learned From The National PCI Registry

PROMUS Element Experience In AMC

Debate Should we use FFR? I will say NO.

Unprotected LM intervention

PCIs on Intermediate Lesions NCDR Cath-PCI Registry

Safety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD

Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial

Benefit of Performing PCI Based on FFR

Coronary interventions

Fractional Flow Reserve: Review of the latest data

Plaque Shift vs. Carina Shift Prevalence and Implication

Clinical case in perspective. Cases from Poland

What do the guidelines say?

DEB experience in Gachon Universtiy Gil Hospital (in ISR) Soon Yong Suh MD., PhD. Heart Center Gachon University Gil Hospital Seoul, Korea.

Periprocedural Myocardial Infarction and Clinical Outcome In Bifurcation Lesion

Bifurcation stenting with BVS

The MAIN-COMPARE Study

Σεμινάριο Ομάδων Εργασίας Fractional Flow Reserve (FFR) Σε ποιούς ασθενείς; ΔΗΜΗΤΡΗΣ ΑΥΖΩΤΗΣ Επιστ. υπεύθυνος Αιμοδυναμικού Τμήματος, Βιοκλινική

Percutaneous Intervention of Unprotected Left Main Disease

PCI for Left Main Coronary Artery Stenosis. Jean Fajadet Clinique Pasteur, Toulouse, France

Alex versus Xience Registry Preliminary report

Left Main and Bifurcation Summit I. Lessons from European LM Studies

A Paclitaxel-Eluting Balloon for Bifurcation Lesions : Early Clinical Observations

ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions

Unprotected Left Main Stenting: Patient Selection and Recent Experience. Alaide Chieffo. S. Raffaele Hospital, Milan, Italy

Fractional Flow Reserve: Basics, FAME 1, FAME 2. William F. Fearon, MD Associate Professor Stanford University Medical Center

Perioperative Management After Coronary Stenting: Risk Assessment Before Surgery. Christian Seiler No conflict of interest to declare.

TCTAP Upendra Kaul MD,DM,FACC,FSCAI,FAMS,FCSI

Integrated Use of IVUS and FFR for LM Stenting

Can Angiographic Complete Revascularization Improve Outcomes for Patients with Decreased LV Function? NO!

FFR and CABG Emanuele Barbato, MD, PhD, FESC Cardiovascular Center Aalst, Belgium

Declaration of conflict of interest. Nothing to disclose

Final Kissing Ballooning Returns? The analysis of COBIS II registry

FFR in Multivessel Disease

Instantaneous Wave-Free Ratio

Coronary stenting: the appropriate use of FFR

J. Schwitter, MD, FESC Section of Cardiology

EBC London 2013 Provisional SB stenting strategy with kissing balloon with Absorb

IVUS-Guided d Provisional i Stenting: Plaque or Carina Shift. Soo-Jin Kang, MD., PhD.

Anatomical, physiological and clinical relevance of a side branch

Percutaneous Coronary Interventions Without On-site Cardiac Surgery

IVUS vs FFR Debate: IVUS-Guided PCI

Fractional Flow Reserve and the Results of the FAME Study

OCT guidance for distal LM lesions

So-Yeon Choi, MD., PhD. Department of Cardiology Ajou University School of Medicine, Korea

Impact of Thromboaspiration during Primary PCI on infarcted segmental myocardial function: a Tissue Doppler imaging evaluation. EXPIRA Trial substudy.

Stable Angina: Indication for revascularization and best medical therapy

Revascularization after Drug-Eluting Stent Implantation or Coronary Artery Bypass Surgery for Multivessel Coronary Disease

Evaluation of Intermediate Coronary lesions: Can You Handle the Pressure? Jeffrey A Southard, MD May 4, 2013

Imaging ischemic heart disease: role of SPECT and PET. Focus on Patients with Known CAD

PCI for Long Coronary Lesion

Patient. Clinical data Indications: Operation date. Comorbidities: Patient code Birth date: / /

CHRONIC HEART FAILURE : WHAT ELSE COULD WE OFFER TO OUR PATIENTS? Cardiac Rehabilitation Society of Thailand

FRACTIONAL FLOW RESERVE: STANDARD OF CARE

UPDATE ON THE MANAGEMENTACUTE CORONARY SYNDROME. DR JULES KABAHIZI, Psc (Rwa) Lt Col CHIEF CONSULTANT RMH/KFH 28 JUNE18

CASE from South Korea

Mid-term results from real-world REPARA registry. Felipe Hernandez, on behalf of the REPARA investigators

STENTYS for Le, Main Sten2ng. Carlo Briguori, MD, PhD Clinica Mediterranea Naples, Italy

Final Clinical and Angiographic Results From a Nationwide Registry of FIREBIRD Sirolimus- Eluting Stent: Firebird In China (FIC) Registry (PI R. Gao)

Contemporary therapy of bifurcation lesions

Intervention: How and to which extent is technology helping us?

Clinical Summary. Live Cases I - IX

Perioperative Cardiology Consultations for Noncardiac Surgery Ischemic Heart Disease

Flexibility of the COMBO Dual Therapy Stent

Insight from the CACTUS trial Coronary Bifurcation Application of the Crush

New Insight about FFR and IVUS MLA

PCI for Left Anterior Descending Artery Ostial Stenosis

Zachary I. Hodes, M.D., Ph.D., F.A.C.C.

Three-Year Clinical Outcomes with Everolimus-Eluting Bioresorbable Scaffolds: Results from the Randomized ABSORB III Trial Stephen G.

Case Report Left Main Stenosis. Percutaneous Coronary Intervention (PCI) or Coronary Artery Bypass Graft Surgery (CABG)?

EXCEL vs. NOBLE: How to Treat Left Main Disease in 2017 AATS International Cardiovascular Symposium December 8-9, 2017

Cardiologic history. Anamnesis. Female BD Risk factors HTN, DM, Dyslipidaemia. Cardiologic Long history. Last admission Heart failure

Assessing Cardiac Risk in Noncardiac Surgery. Murali Sivarajan, M.D. Professor University of Washington Seattle, Washington

Indications of Coronary Angiography Dr. Shaheer K. George, M.D Faculty of Medicine, Mansoura University 2014

Paris, August 28 th Gian Paolo Ussia on behalf of the CoreValve Italian Registry Investigators

COMMENT DEFINIR UN PLURITRONCULAIRE. Didier Carrié CHU Toulouse Rangueil

Cindy L. Grines MD FACC FSCAI

Le# main treatment with Stentys stent. Carlo Briguori, MD, PhD Clinica Mediterranea Naples, Italy

FFR-guided Complete vs. Culprit Only Revascularization in AMI Patients Ki Hong Choi, MD On Behalf of FRAME-AMI Investigators

Resolute in Bifurcation Lesions: Data from the RESOLUTE Clinical Program

Total occlusion at ostial Left internal mammary graft with successful angioplasty and longterm patency result

6 th European Bifurcation Club October BUDAPEST. Kissing in simple strategy? Why and how I kiss. Y. Louvard, ICPS, Massy France

The Tryton Side Branch System in Distal Left Main PCI

Basics of Angiographic Interpretation Analysis of Angiography

Welcome to the 8 th European Bifurcation Club October Barcelona

Between Coronary Angiography and Fractional Flow Reserve

Incidence and Treatment for LM In-Stent

Update from the Tryton IDE study

Fractional Flow Reserve Guided PCI versus Medical Therapy in Stable Coronary Disease. FAME 2 Trial

A Normal Reference Coronary Flow Reserve is Associated With a Lower Mortality in Patients With Stable Coronary Artery Disease

Calculation of the Index of Microcirculatory Resistance without Coronary Wedge Pressure Measurement in the Presence of Epicardial Stenosis

A Polymer-Free Dual Drug-Eluting Stent in Patients with Coronary Artery Disease: Randomized Trial Versus Polymer-Based DES.

Fractional Flow Reserve. A physiological approach to guide complex interventions

Transcription:

FFR vs. icecg in Coronary Bifurcations (FIESTA) - preliminary results Dobrin Vassilev MD, PhD National Heart Hospital Sofia, Bulgaria

I would like to express my personal gratitude to Dr. BK Koo for opening my eyes about potential of icecg On behalf of all FIESTA and COSIBRIA & Co investigators: the teams of National Heart Hospital, Sofia, MedicaCore Heart Hospital, Russe, Bulgaria, CSK MSWiA Warsaw, Poland ClinicalTrials.gov Identifiers: NCT01724957 & NCT01268228 Nothing to disclose regarding this presentation

Our target is ischemia! Hachamovitch et al. Circulation. 2003;107:2900-2906

What we don t know during bifurcation PCI? If patient is asymptomatic and ECG is normal is there ischemia in treated region? Does SB compromise cause ischemia? During the procedure? After the procedure? What is importance of end-procedural ischemia?

FFR is the invasive standard for ischemia detection! Park & Koo Journal of Geriatric Cardiology (2012) 9: 278 284

SB%DS after stenting does not correlate with ischemia! Koo et al. European Heart Journal (2008) 29, 726 732

The results based on FFR in bifurcations are sustained at one year Koo et al. European Heart Journal (2008) 29, 726 732

The alternative - ic ECG mapping Vassilev et al. J. Am. Coll. Cardiol., 2011; 58: B81.

COronary SIde Branch Residual IschemiA and COllateralization Assessment Study (COSIBRIA & Co Study) Study aims To compare occurrence of ischemia in MB and SB during the procedure To establish sensitivity of a method for detection of significant SB region ischemia after stenting To assess sensitivity and specificity of a method to predict periprocedural myonecrosis and to localize the area/s with residual ischemia To assess possible long-term influence of periprocedural ischemia

Inclusion criteria Subject at least 18 years of age. Stabile or unstable angina; Subject able to verbally confirm understandings of risks, benefits of receiving PCI for true bifurcation lesions, and he/she or his/her legally authorized representative provides written informed consent prior to any study related procedure. Target vessel with last lesion remaining for treatment; Main branch lesion(s) located in a native coronary artery with diameter of 2.5 mm and 4.5 mm. Target side branch lesion(s) located in a native coronary artery with diameter of 2.0 mm. Target lesion(s) amenable for PCI with balloon angioplasty of the side branch.

Exclusion criteria Subjects with significant ST-T change ( 1mm). Non-cardiac co-morbid conditions are present with life expectancy <1 year or that may result in protocol non-compliance (per site investigator's medical judgment). Subjects with the following angiographic characteristics: left main coronary artery stenosis, total occlusion before occurrence of SB, lesion of interest located at infarct-related artery. Subjects with LVEF < 30%. Subjects with moderate or severe degree valvular heart disease or primary cardiomyopathy. LBBB, RBBB, atrial fibrillation/flutter with no identifiable isoelectric line.

Demographics Age, years 68±8 Sex, males 69% CCS class 3 (including UA) 51% NYHA class 3 19% Hypertension 97% Family history for CAD 12% Dyslipidemia 90% Smoking 34% Diabetes 34% Cancer 5% PAD 9% CVD 11% Renal failure 9% COPD 14% Previous MI 38% Previous CABG 2% Previous PCI 52%

COSIBRIA results SB%DS is not associated with icecg STE

COSIBRIA results P=.037 P=.031 P<.001

COSIBRIA results MACE Angina or new onset CHF 31,9 30,6 p =.064 18 p =.051 16 Tn (+) Tn (-)

Fractional Flow Reserve Versus Intracoronary ECG for Detection of Post Stenting Ischemia in Side Branch Territory in coronary Bifurcation Lesions (FIESTA) Study aims to verify in head-to-head comparison ability to detect periprocedural ischemia of FFR vs. icecg to verify ability of icecg to identify ischemia generating (hemodynamically significant?) SB stenosis at the ostium of side branches

FIESTA Started in December 2012 34 pts screened with FFR at the beginning of PCI 15 pts enrolled, the rest ns FFR Anticipated number of pts to be enrolled 40

TYPICAL EXCLUSION CASE FFR 0.91 FFR 0.79

icecg (+), FFR (-) STE = 4.7 MM FFR = 0.88

icecg (+), FFR (-) Final result after POBA SB (2.0/8mm/14atm) next day Tn 0.1 (before PCI 0.01) icecg STE 2.0 mm FFR = 0.91

icecg (-), FFR (++) FFR = 0.58 icecg <0.5 mm

icecg (-), FFR (++) Final result after POBA SB 1.5/15mm/15 atm next day Tn 0.01 icecg <0.5 mm FFR = 0.75

icecg (+), FFR (+) icecg STE 7 mm FFR = 0.45

icecg (+), FFR (+) Final result after KBI icecg STE <0.5 mm next day Tn 0.01 FFR = 0.83

Can FFR detect periprocedural ischemia or just potential postprocedural ischemia? Final icecg STE 4 mm in MB at stent region FFR normal range LAD 0.87; D2 0.83

After stenting FFR <.80 FFR >.80 IcECG (+) 2 2 IcECG (-) 2 9 FFR.76 &.58 Final FFR <.80 FFR >.80 IcECG (+) 1 2 IcECG (-) 1 11 FFR.75 Possible distal embolism, microcirculatory spasm

Conclusions: Periprocedural ischemia is associated with long term outcomes TLR, MI, New onset angina/chf We still did not observed case with FFR<.75 and no ischemia on final ic ECG Ic ECG reveals other mechanisms for ischemia occurrence than significant ostial stenosis at SB ostium

THANK YOU FOR YOUR ATTENTION!